Biosyntech Performance

The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Biosyntech are completely uncorrelated.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Biosyntech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Biosyntech is not utilizing all of its potentials. The newest stock price confusion, may contribute to short-horizon losses for the traders. ...more
  

Biosyntech Relative Risk vs. Return Landscape

If you would invest (100.00) in Biosyntech on November 13, 2025 and sell it today you would earn a total of  100.00  from holding Biosyntech or generate -100.0% return on investment over 90 days. Biosyntech is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Biosyntech, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  

Biosyntech Target Price Odds to finish over Current Price

The tendency of Biosyntech Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.00 90 days 0.00 
about 54.85
Based on a normal probability distribution, the odds of Biosyntech to move above the current price in 90 days from now is about 54.85 (This Biosyntech probability density function shows the probability of Biosyntech Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Biosyntech has the beta coefficient that is very close to zero suggesting the returns on DOW JONES INDUSTRIAL and Biosyntech do not appear to be responsive. Additionally It does not look like Biosyntech's alpha can have any bearing on the current valuation.
   Biosyntech Price Density   
       Price  

Predictive Modules for Biosyntech

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biosyntech. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biosyntech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details

Biosyntech Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Biosyntech is not an exception. The market had few large corrections towards the Biosyntech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Biosyntech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Biosyntech within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.00
β
Beta against Dow Jones0.00
σ
Overall volatility
0.0004
Ir
Information ratio 0.00

Biosyntech Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biosyntech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biosyntech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Biosyntech is not yet fully synchronised with the market data
Biosyntech has some characteristics of a very speculative penny stock
Biosyntech has a very high chance of going through financial distress in the upcoming years
The company has a current ratio of 0.21, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biosyntech until it has trouble settling it off, either with new capital or with free cash flow. So, Biosyntech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biosyntech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biosyntech to invest in growth at high rates of return. When we think about Biosyntech's use of debt, we should always consider it together with cash and equity.
Biosyntech reported the previous year's revenue of 5.06 K. Net Loss for the year was (12.94 M) with profit before overhead, payroll, taxes, and interest of 24.8 K.
Biosyntech currently holds about 1.44 M in cash with (9.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.

Biosyntech Fundamentals Growth

Biosyntech Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Biosyntech, and Biosyntech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biosyntech Pink Sheet performance.

About Biosyntech Performance

By evaluating Biosyntech's fundamental ratios, stakeholders can gain valuable insights into Biosyntech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biosyntech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biosyntech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. On May 12, 2010, Biosyntech Inc. filed for administration under the Bankruptcy and Insolvency Act. BIOSYNTECH INC is traded on PNK Exchange in the United States.

Things to note about Biosyntech performance evaluation

Checking the ongoing alerts about Biosyntech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Biosyntech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Biosyntech is not yet fully synchronised with the market data
Biosyntech has some characteristics of a very speculative penny stock
Biosyntech has a very high chance of going through financial distress in the upcoming years
The company has a current ratio of 0.21, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biosyntech until it has trouble settling it off, either with new capital or with free cash flow. So, Biosyntech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biosyntech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biosyntech to invest in growth at high rates of return. When we think about Biosyntech's use of debt, we should always consider it together with cash and equity.
Biosyntech reported the previous year's revenue of 5.06 K. Net Loss for the year was (12.94 M) with profit before overhead, payroll, taxes, and interest of 24.8 K.
Biosyntech currently holds about 1.44 M in cash with (9.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Evaluating Biosyntech's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Biosyntech's pink sheet performance include:
  • Analyzing Biosyntech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biosyntech's stock is overvalued or undervalued compared to its peers.
  • Examining Biosyntech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Biosyntech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biosyntech's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Biosyntech's pink sheet. These opinions can provide insight into Biosyntech's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Biosyntech's pink sheet performance is not an exact science, and many factors can impact Biosyntech's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Consideration for investing in Biosyntech Pink Sheet

If you are still planning to invest in Biosyntech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biosyntech's history and understand the potential risks before investing.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges